|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diltiazem#Adverse Reactions]] |
| {{Diltiazem}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==ADVERSE REACTIONS==
| |
| | |
| Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies.
| |
| | |
| In the hypertension study, the following table presents adverse reactions more common on diltiazem than on placebo (but excluding events with no plausible relationship to treatment), as reported in placebo-controlled hypertension trials in patients receiving a diltiazem hydrochloride extended-release formulation (once-a-day dosing) up to 540 mg.
| |
| | |
| [[image:cardizem2.png]]
| |
| | |
| In the angina study, the adverse event profile of CARDIZEM LA was consistent with what has been previously described for CARDIZEM LA and other formulations of diltiazem HCl. The most frequent adverse effects experienced by CARDIZEM LA-treated patients were [[edema ]]lower-limb (6.8%), [[dizziness ]](6.4%), [[fatigue ]](4.8%), [[bradycardia ]](3.6%), [[first-degree atrioventricular block ]](3.2%), and cough (2%).
| |
| | |
| In clinical trials of other diltiazem formulations involving over 3200 patients, the most common events (i.e., greater than 1%) were [[edema ]](4.6%), [[headache ]](4.6%), dizziness (3.5%), [[asthenia ]](2.6%), [[first-degree AV block]] (2.4%), [[bradycardia ]](1.7%), [[flushing ]](1.4%), [[nausea ]](1.4%), and [[rash ]](1.2%).
| |
| | |
| In addition, the following events were reported infrequently (less than 1 %):
| |
| | |
| '''Cardiovascular:''' [[Angina]], [[arrhythmia]],[[ AV block ]]([[first-degree AV block| first-degree]]), AV block ([[second degree AV block|second-]] or [[third degree AV block|third-degree –]] see [[Diltiazem hydrochloride tablet warnings|WARNINGS, Cardiac Conduction]]), [[bradycardia]], [[bundle branch block]], [[congestive heart failure]], [[ECG]] abnormality, [[flushing]], [[hypotension]], [[palpitations]], [[syncope]], [[tachycardia]], [[ventricular extrasystoles]].
| |
| | |
| '''Nervous System:''' Abnormal dreams, [[amnesia]], [[depression]], [[gait ]]abnormality, [[hallucinations]], [[insomnia]], [[nervousness]], [[paresthesia]], personality change, [[somnolence]], [[tremor]].
| |
| | |
| '''Gastrointestinal:''' [[Anorexia]], [[constipation]], [[diarrhea]], [[dysgeusia]], [[dyspepsia]], mild elevations of [[alkaline phosphatase]], [[SGOT]], [[SGPT]], and [[LDH ]](see [[Diltiazem hydrochloride tablet warnings|WARNINGS, Acute Hepatic Injury]]), [[thirst]], [[vomiting]], weight increase.
| |
| | |
| '''Dermatological:''' [[Petechiae]], [[photosensitivity]], [[pruritus]], [[urticaria]].
| |
| | |
| '''Other:''' [[Amblyopia]], [[CPK ]]elevation, dry mouth, [[dyspnea]], [[epistaxis]], eye irritation, [[hyperglycemia]], [[hyperuricemia]], [[impotence]], [[muscle cramps]], nasal congestion, [[nocturia]], [[osteoarticular pain]], [[polyuria]], [[sexual difficulties]], [[tinnitus]].
| |
| | |
| The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: acute generalized exanthematous [[pustulosis]], allergic reactions, [[alopecia]], [[angioedema ]](including facial or [[periorbital edema]]), [[asystole]], [[erythema multiforme]] (including [[Stevens-Johnson syndrome]], [[toxic epidermal necrolysis]]), [[extrapyramidal symptoms]], [[gingival hyperplasia]], [[hemolytic anemia]], increased [[bleeding time]], [[leukopenia]], [[photosensitivity ]](including lichenoid keratosis and [[hyperpigmentation ]]at sun-exposed skin areas), [[purpura]], [[retinopathy]], [[myopathy]], and [[thrombocytopenia]]. There have been observed cases of a generalized rash, some characterized as [[leukocytoclastic vasculitis]]. In addition, events such as[[ myocardial infarction]] have been observed, which are not readily distinguishable from the natural history of the disease in these patients. A definitive cause and effect relationship between these events and CARDIZEM therapy cannot yet be established. [[Exfoliative dermatitis]] (proven by rechallenge) has also been reported.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CARDIZEM LA (DILTIAZEM HYDROCHLORIDE) TABLET, EXTENDED RELEASE [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4626a8d-a28d-4937-aa61-b9d958ae336c | publisher = | date = | accessdate = 5 March 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |